

Investigating the association between fasting insulin, erythrocytosis and HbA1c through Mendelian randomization and observational analyses

Anthony Nguyen*¹, Rana Khafagy*^{1,2,3}, Habiba Hashemy¹, Kevin H.M. Kuo^{4,5,6}, Delnaz Roshandel², Andrew D. Paterson^{2,3} & Satya Dash¹

¹ Department of Medicine, University Health Network, Toronto & University of Toronto

² Genetics and Genome Biology Program, the Hospital for Sick Children, Toronto

³ Divisions of Epidemiology and Biostatistics, Dalla Lana School of Public Health, University of Toronto

⁴ Division of Medical Oncology and Haematology, Department of Medicine, University Health Network

⁵ Division of Haematology, Department of Medicine, University of Toronto

⁶ Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto

* These authors contributed equally

Correspondence:

Dr. Satya Dash

Toronto General Hospital,

200 Elizabeth Street

Toronto, Ontario

Canada M5G 2C4

Abstract:

Background: Insulin resistance (IR)/hyperinsulinemia (HI), are early abnormalities in the etiology of prediabetes (preT2D) and type 2 diabetes (T2D). IR/HI also associate with increased erythrocytosis. Hemoglobin A1c (HbA1c) is commonly used to diagnose and monitor preT2D/T2D, but can be influenced by erythrocytosis independent of glycemi.

Methods: We undertook bidirectional Mendelian randomization (MR), in individuals of European ancestry, to investigate potential causal associations between increased fasting insulin adjusted for BMI (FI), erythrocytosis and its non-glycemic impact on HbA1c. We investigated the association between Triglyceride-glucose index (TGI), a surrogate measure of IR/HI, and glycation gap (difference between measured HbA1c and predicted HbA1c derived from linear regression of fasting glucose) in people with normoglycemia and preT2D.

Results: Inverse variance weighted MR (IVWMR) suggests increased FI increases haemoglobin ($b=0.54\pm 0.09$, $p=2.7 \times 10^{-10}$), red cell count (RCC, $b=0.54\pm 0.12$, $p=5.38 \times 10^{-6}$) and reticulocyte (RETIC, $b=0.70\pm 0.15$, $p=2.18 \times 10^{-6}$). Multivariable MR indicates increased FI does not impact HbA1c ($b=0.23\pm 0.16$, $p=0.162$) but reduces HbA1c after adjustment for T2D ($b=0.31\pm 0.13$, $p=0.016$). Increased haemoglobin ($b=0.03\pm 0.01$, $p=0.02$), RCC ($b=0.02\pm 0.01$, $p=0.04$) and RETIC ($b=0.03\pm 0.01$, $p=0.002$) might modestly increase FI. Increased TGI associates with decreased glycation gap, i.e. measured HbA1c was lower than expected based on fasting glucose, ($b=-0.09\pm 0.009$, $p<0.0001$) in people with preT2D but not in normoglycemia ($b=0.02\pm 0.007$, $p<0.0001$).

Conclusions: MR suggests increased FI increases erythrocytosis and might potentially decrease HbA1c by non-glycemic effects. Increased TGI, a surrogate measure of increased FI, associates

with lower-than-expected HbA1c in people with preT2D. These findings merit confirmatory studies to evaluate its clinical significance.

Introduction

The type 2 diabetes (T2D) pandemic is a major public health challenge which now affects more than 420 million people worldwide (1,2). Insulin resistance (IR) and hyperinsulinemia (HI) are early abnormalities in the pathogenesis of prediabetes (preT2D) and T2D (3). Close surveillance and timely intervention in people with IR/HI and preT2D can potentially prevent T2D and remit/improve glycemia in those who do develop T2D (4–6).

Increasingly, haemoglobin A1c (HbA1c) has replaced fasting glucose and/or the 75 g oral glucose tolerance test to diagnose preT2D, T2D and T2D remission. HbA1c is also used to set glycemic targets for people with diabetes (7–9). Advantages to using HbA1c compared to fasting glucose, include convenience and use of an assay that is standardized, stable, reproducible with limited intraindividual variability (1,10). It provides an average measure of glycemia in the preceding 2 to 3 months (1). However, altered red cell lifespan and erythrocytosis, which is not routinely assessed, can affect HbA1c measurement by non-glycemic pathways, which has implications in patients with red cell disorders and haemoglobinopathies (1,11). In people without T2D, including those with preT2D, non-glycemic parameters are a major predictor of HbA1c: higher haemoglobin associates with lower HbA1c (12,13). Observational studies have also shown an association between IR/HI and increased haemoglobin and red cell count (14–16), but whether this association is causal is not established, nor is it known whether this impacts HbA1c measurement through non-glycemic pathways.

Mendelian randomization (MR) can be used to infer potential causal associations between an exposure and an outcome by assessing the effects of genetic variants robustly associated with the exposure in one population, on the outcome of interest in a separate cohort (2 sample MR)

(17). We undertook bidirectional MR to investigate potential causal associations between fasting insulin adjusted for BMI (FI) and erythrocytosis (haemoglobin, red cell count and reticulocyte count) in people of European ancestry using summary statistics from the largest genome wide association studies (GWAS). We undertook multivariable MR to assess the non-glycemic effects of FI on HbA1c after adjusting for elevated fasting glucose (FG) and type 2 diabetes (T2D). We also explored the association between triglyceride-glucose index (18), a surrogate measure of IR/HI and glycation gap (difference between measured HbA1c and predicted HbA1c from fasted glucose measurement) in people with normoglycemia and preT2D.

Methods

Cohorts

Please see Supplementary File 1 for information outlining cohorts used for MR analyses (19–25).

Primary MR analyses

For our primary analysis we undertook bidirectional inverse variance weighted (IVW) MR with FI as exposure (Supplementary File 3) and Hb, red cell count (RCC), reticulocyte count (RETIC) as outcomes. A p value of <0.05 was considered significant for primary and secondary analyses. We followed the recently published STROBE-MR reporting guidelines (Checklist in Supplementary File 2)(26). As we used publicly available summary statistics from GWAS, we did not seek institutional approval. Informed consent was obtained from the investigators from each participant in the original study.

Secondary analyses

As we found a potential causal association between FI and erythrocytosis, we undertook univariable MR to investigate the association between FI and HbA1c followed by multivariable MR adjusted for FG, T2D and Hb.

MR assumptions: MR is based on three assumptions. First, the instrument is robustly associated with the exposure, therefore we only used SNPs that were genome-wide significantly associated for all the instruments (17). Second that the instrument does not influence the outcome via another pathway other than the outcome i.e. no horizontal pleiotropy (17). Finally, the instrument is not influenced by any confounders (17). For univariable MR, we used inverse weighted MR (IVWMR) and additional sensitivity analyses including MR-Egger, weighted median, weighted mode and leave-one-out analyses.

IVWMR was performed by undertaking meta-analysis of the individual Wald ratio for each SNP in the instrument. By permitting a non-zero intercept, MR-Egger relaxes the assumption of no horizontal pleiotropy and returns an unbiased causal estimate, in the case of horizontal pleiotropy, providing that the horizontal pleiotropic effects are not correlated with the SNP-exposure effects (InSIDE assumption) (17,27). The median effect of all SNPs in the instrument was used for analysis using weighted median MR, which permits SNPs with a greater effect on the association to be evaluated by weighting the contribution of each SNP by the inverse variance of its association with the outcome: this is robust even if only 50% of the SNPs satisfy all three MR assumptions (28). Finally, SNPs were clustered into groups based on similarity of causal effects for weighted mode MR, with the cluster with the largest number of SNPs deriving the causal effect estimate (29). Cochran's Q test was used to assess heterogeneity, while leave-one-out analyses were conducted to assess if any MR estimate was biased by a single SNP potentially

with horizontal pleiotropic effect (17) and the F statistic was calculated to assess the strength of the instrument exposure (17,30,31).

Univariable MR was conducted using the “TwoSampleMR” package in R (R studio® v1.3.1073 and R® v4.0.3). Linkage disequilibrium (LD) pruning was used to select a proxy ($r^2 > 0.8$) if a SNP was not directly matched from the 1000 Genomes project (Version 0.5.6, Released 2021-03-35). The “ggplot2” and “metaphor” packages in R were used to create plots. We undertook inverse variance weighted multivariable MR (IVW Multivariable MR) to assess the effect of FI on HbA1c after adjustment for FG and T2D as well as Hb (32). Multivariable MR was conducted using both the “TwoSampleMR”, “Multivariable MR” and “RMultivariable MR” packages in R (R studio® v1.3.1073 and R® v4.0.3) where the latter two packages assessed heterogeneity via Cochran’s Q test and strength of the instrument via F statistics (30,32). Plots were generated using “plotobject”.

Overlap between exposure and outcome cohorts

There is no reported overlap between the cohorts.

Observational Study

We received institutional approval from UHN research ethics board for the observational study. As we analyzed anonymized data, we did not obtain consent from individual patients. We undertook further analyses in a cohort of patients without T2D (n=7600 of whom 1096, i.e. 14.4%, have pre-T2D), who attended University Health Network (UHN) outpatient clinics between 2006 and 2022. We excluded patients who had attended diabetes clinics in the prior 2 years, those with fasting glucose ≥ 7 mmol/L, HbA1c $\geq 6.5\%$, age >65 years or <18 years or Hb outside the sex-specific normal range. We did not undertake analyses in patients with diabetes

as we did not have access to their medical records and could not ascertain the type of diabetes or their medications (e.g. insulin and sodium glucose co-transporter 1 inhibitors) which can impact both glycemia and erythrocytosis (33,34)

Using R studio® v1.3.1073 and R® v4.0.3, predicted HbA1c was assessed based on regression analysis of fasting glucose adjusted for age and sex. Glycation gap was calculated as the difference between measured HbA1c and predicted HbA1c. We assessed the association between triglyceride-glucose index(18), a surrogate measure of IR/HI, and the glycation gap. Triglyceride-glucose index (18) was calculated as $\ln[\text{fasting triglyceride (mg/dL)} \times \text{fasting plasma glucose (mg/dL)} / 2]$. Correction factors of 88.57 and 18 were used to convert triglycerides to mg/L and fasting glucose to mg/dL, respectively.

The rms and lattice packages were used to fit a regression model and for estimation. The beta coefficient, standard error, y-intercept and p-value were analyzed in order to determine if there was an association between triglyceride-glucose index and glycation gap for all participants, those with pre-T2D (HbA1c 6-6.4% and fasting glucose 6-6.9 mmol/l) and those with normoglycemia (specified as HbA1c < 6% and fasting glucose <6 mmol/l). A p-value of < 0.05 was specified as being significant. The R^2 and adjusted R^2 were also analyzed to determine the fit of the model. An ANOVA table further analyzed if there was a linear relationship present.

Several diagnostic plots were created to test the presence of linearity and evaluate the fit of our model. A Normal Q-Q plot was created to test if the data had a normal distribution. If the data points fell onto a reasonably straight line, this would indicate a well fit model. Using the xyplot function, two plots were then created, both examining the residuals (residuals versus fitted values and residuals versus triglyceride-glucose index). If the plots produced a straight line, this

would indicate a linear relationship. If the line was curved, this would indicate nonlinearity and splines would be required to analyze the cubic model.

Finally, the model was assessed for overfitting via validation. A set of random numbers was generated and the 0.632 Bootstrap method was used (35). The 0.632 Bootstrap method was chosen as to reduce bias by using correction factors. The R^2 and mean squared error (MSE) were analyzed. An overfit model would produce a significantly different R^2 and a higher MSE. Further, an optimism greater than 0.1 would suggest overfitting, as well as a slope with shrinkage. A decrease in g-index would also be suggestive of overfitting. It should be noted that MSE and g-index may be difficult to interpret as they vary based on sample size and range of data. The same analyses were undertaken for triglyceride-glucose index on Hb.

Results

1. Primary analyses

Univariable MR Analyses of FI and erythrocytosis (Hb, RCC, RETIC)

Univariable inverse variance weighted MR suggests increased FI increases Hb ($b=0.54\pm 0.09$, $p=2.7\times 10^{-10}$, RCC ($b=0.54\pm 0.012$, $p=5.38\times 10^{-6}$) and RETIC ($b=0.70\pm 0.15$, $p=2.18\times 10^{-6}$), with concordant results with MR-Egger, weighted median, weighted mode and simple mode MR analyses. (Table 1, Figure 1-2).

Inverse variance weighted MR suggests increased Hb ($b=0.03\pm 0.01$, $p=0.02$), RCC ($b=0.02\pm 0.01$, $p=0.04$) and RETIC ($b=0.03\pm 0.01$, $p=0.002$) might modestly increase FI, but MR-Egger, weighted median, weighted mode and simple mode MR analyses did not find evidence for potential causal association (Supplementary File 4)

2. Secondary analyses

Univariable and Multivariable MR Analyses of FI as exposure (adjusted for FG, T2D and Hb) and HbA1c as outcome

Univariable inverse variance weighted MR suggests that increased FI does not significantly increase HbA1c ($b=0.23\pm 0.16$, $p=0.16$). Multivariable MR suggests FI decreases HbA1c after adjusting for T2D ($b=-0.30\pm 0.13$, $p=0.02$. After adjusting for Hb ($b=0.36$, $p=9.14\times 10^{-4}$), FI increases HbA1c, but the F-statistic of <10 precludes definitive conclusion. There was no significant effect of FI on HbA1c after adjusting for FG alone ($b=-0.221\pm 0.13$, $p=0.096$) (Table 3, Figure 3, Supplementary File 5).

3. Exploratory Analyses

MR Analyses exploring association between Hb and HbA1c

MR suggests a bidirectional relationship between Hb and HbA1c. Univariable inverse variance weighted MR suggests increased Hb decreases HbA1c ($b=-0.105$, $p=1.17 \times 10^{-13}$) concordant with MR-Egger, weighted median and mode but not simple mode analyses (Supplementary File 6). Reverse inverse variance weighted MR suggests increased HbA1c decreases Hb ($b=-0.867$, $p=6.02 \times 10^{-7}$) concordant with MR-Egger, weighted median and simple mode but not weighted mode analyses (Supplementary File 6).

Observational Study

Descriptive statistics regarding the 7600 participants can be found in Supplemental File 7. Consistent with the MR analyses, increased TGI was associated with increased Hb ($b=1.88 \pm 0.19$, $p<0.001$) (Figure 4a). Linear regression analysis yielded this equation for predicted HbA1c derived from fasting glucose and adjusted for age and sex: $4.163 + 0.172 * (\text{fasting glucose})$. In the cohort overall (the majority of whom had normoglycemia), ($b=0.073 \pm 0.008$, $p<0.0001$) and in people with normoglycemia ($b=0.023 \pm 0.007$, $p<0.0001$), increased triglyceride-glucose index was associated with an increase in glycation gap. However, among people with pre-T2D, increased triglyceride-glucose index was associated with a decreased glycation gap i.e. measured HbA1c was lower than that predicted by fasting glucose ($b=-0.087 \pm 0.009$, $p<0.0001$) (Figure 4b-d). For all analyses, the R^2 adjusted and unadjusted were almost identical and the regression p-values were <0.005 . Normal Q-Q plots for all data were suggestive of a normal distribution and good fit. Plots for residuals versus triglyceride-glucose index and residuals versus fitted values suggested linearity and that likely all relationships were accounted for in the model. Using the 0.632 Bootstrap method, validation was carried out and resulted in corrected R^2 and corrected slopes that were relatively similar to the original values. The R optimism was found to be 0.0116,

which was less than the cut-off of 0.1. The MSE increased by 1.57% and the g-index decreased by 3.97%. These results indicate that the model was not overfit.

Discussion

Epidemiological data suggests that IR/HI is associated with increased erythrocytosis (14–16). Our MR analysis suggests that this association is causal. MR further suggests that increased FI after adjustment for T2D reduces HbA1c. MR also indicates a bidirectional inverse relationship between Hb and HbA1c. Collectively, these data suggest that increased IR/HI mediated erythrocytosis might potentially lower HbA1c by non-glycemic effects with the transition from normoglycemia to T2D. Our observational data was concordant with the MR analyses. shows Increased triglyceride-glucose index, a surrogate measure of IR/HI associated with both higher Hb and measured HbA1c which is lower than expected in people with preT2D, but not in those with normoglycemia. These findings await confirmation and assessment of clinical significance in well designed prospective studies across the glycemic spectrum from normoglycemia to preT2D and T2D.

Increased FI is a recognised manifestation of IR. Some features of IR/HI such as increased hepatic glucose production are likely a consequence of reduced insulin action, while others such as hepatic steatosis and dyslipidemia are likely due to increased insulin action via signaling pathways that are not perturbed in IR (36). *In vitro* studies suggest that insulin can increase erythrocytosis (37), suggesting that increased insulin action may underlie the increased in erythrocytosis with IR/HI. Further studies are needed to confirm these findings and explore underlying mechanisms.

The potential non-glycemic impacts of increased fasting insulin on HbA1c might lead to lower-than-expected HbA1c based on glycemia and thus have implications for people with IR/HI and

preT2D and T2D. HbA1c is increasingly used to diagnose these conditions, in lieu of fasting glucose/oral glucose tolerance test measures, and to set glycemic targets for treatment (1,7–10). Interestingly, observational data indicate that ~40% of people with T2D diagnosed based on more than one measure of elevated fasting glucose and/or post OGTT glucose, have HbA1c below the diabetes threshold (38). The potential non-glycemic effects of increased FI on HbA1c may also be particularly pertinent for weight loss induced T2D diabetes remission. HbA1c is the recommended glycemic parameter to define remission in a patient population with high prevalence of IR/HI (9).

The strengths of this study include MR analyses with the largest sample sizes in populations of European ancestry and likely minimal/no overlap between participants in the exposure and outcome cohorts. Our study has a number of limitations. The findings may not apply to other ethnic groups given that we used populations with European ancestry only. This may especially be a concern in populations with higher prevalence of hemoglobinopathies and red cell disorders (39–43). Additionally, analyses were not stratified by sex, which is a major determinant of body composition and IR/HI (44). For our observational data we did not have access to individual level data including medications and comorbidities. Due to these limitations, we also excluded patients with biochemical evidence of T2D as we could not reliably ascertain the type of diabetes and account for the potential impact of medications which might impact red cell parameters. We derived predicted HbA1c from fasting glucose and did not account for post-prandial readings which are a major limitation. Finally, we did not have measures of FI in the observational cohort and therefore used surrogate measures of IR/HI in our analyses.

In conclusion, our data suggests that increased FI may increase erythrocytosis and might potentially lower HbA1c independent of glycemia. As these findings might have implications for the diagnoses and management of preT2D and T2D, it merits well designed prospective confirmatory studies across the glycemic spectrum to confirm these findings and assess whether these effects are clinically relevant.

Funding

SD is funded by CIHR, Heart & Stroke Foundation of Canada and Banting & Best Diabetes Centre (DH Gales Family Charitable Foundation New Investigator Award and a Reuben & Helene Dennis Scholar in Diabetes Research).

Contributions

SD, ADP, AN and RK designed the study. All authors analyzed the data. AN, RK and SD wrote the manuscript and all authors read and edited the manuscript. SD is the guarantor of this work.

Conflicts of Interest

None

References

1. Selvin E. Hemoglobin A 1c-Using Epidemiology to Guide Medical Practice: Kelly West Award Lecture 2020. *Diabetes Care* [Internet]. *Diabetes Care*; 2021 [cited 2022 Aug 16];44:2197–204. Available from: <https://pubmed.ncbi.nlm.nih.gov/34548283/>
2. WHO Global Report. Global Report on Diabetes. Isbn [Internet]. 2016 [cited 2022 Aug 21];978:11. Available from: http://www.who.int/about/licensing/copyright_form/index.htmlhttp://www.who.int/about/licensing/copyright_form/index.html<https://apps.who.int/iris/handle/10665/204871><http://www.who.int>
3. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. *The Lancet*. Elsevier B.V.; 2009;373:2215–21.
4. Aminian A, Vidal J, Salminen P, Still CD, Hanipah ZN, Sharma G, et al. Late Relapse of Diabetes After Bariatric Surgery: Not Rare, but Not a Failure. *Diabetes Care* [Internet]. *Diabetes Care*; 2020 [cited 2022 Aug 16];43:534–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/31974105/>
5. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol* [Internet]. *Lancet Diabetes Endocrinol*; 2019 [cited 2022 Aug 16];7:344–55. Available from: <https://pubmed.ncbi.nlm.nih.gov/30852132/>
6. Nathan DM, Barrett-Connor E, Crandall JP, Edelstein SL, Goldberg RB, Horton ES, et al. Long-term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications: the DPP Outcomes Study. *Lancet Diabetes Endocrinol* [Internet]. NIH Public Access; 2015 [cited 2022 Aug 16];3:866. Available from: </pmc/articles/PMC4623946/>
7. Berard LD, Siemens R, Pharm B, Woo V. 2018 Clinical Practice Guidelines. 2018 [cited 2022 Aug 16]; Available from: <https://doi.org/10.1016/j.jcjd.2017.10.007>
8. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* [Internet]. *Diabetologia*; 2018 [cited 2022 Aug 16];61:2461–98. Available from: <https://pubmed.ncbi.nlm.nih.gov/30288571/>
9. Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. *Diabetes Care* [Internet]. *Diabetes Care*; 2021 [cited 2022 Aug 16];44:2438–44. Available from: <https://pubmed.ncbi.nlm.nih.gov/34462270/>
10. Reed J, Bain S, Kanamarlapudi V. A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. *Diabetes Metab Syndr Obes*. Dove Medical Press Ltd; 2021. page 3567–602.
11. Lacy ME, Wellenius GA, Sumner AE, Correa A, Carnethon MR, Liem RI, et al. Association of Sick Cell Trait With Hemoglobin A1c in African Americans. *JAMA* [Internet]. American Medical Association; 2017 [cited 2022 Aug 16];317:507–15. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2600468>

12. Fizelova M, Stančáková A, Lorenzo C, Haffner SM, Cederberg H, Kuusisto J, et al. Glycated Hemoglobin Levels Are Mostly Dependent on Nonglycemic Parameters in 9398 Finnish Men Without Diabetes. *J Clin Endocrinol Metab* [Internet]. Oxford Academic; 2015 [cited 2022 Aug 16];100:1989–96. Available from: <https://academic.oup.com/jcem/article/100/5/1989/2829717>
13. Jansen H, Stolk RP, Nolte IM, Kema IP, Wolffenbuttel BHR, Snieder H. Determinants of HbA1c in nondiabetic Dutch adults: Genetic loci and clinical and lifestyle parameters, and their interactions in the lifelines cohort study. *J Intern Med*. 2013;273:283–93.
14. Barazzoni R, Cappellari GG, Semolic A, Chendi E, Ius M, Situlin R, et al. The Association between Hematological Parameters and Insulin Resistance Is Modified by Body Mass Index – Results from the North-East Italy MoMa Population Study. *PLoS One* [Internet]. Public Library of Science; 2014 [cited 2022 Aug 16];9:e101590. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0101590>
15. Woo M, Hawkins M. Beyond Erythropoiesis: Emerging Metabolic Roles of Erythropoietin. *Diabetes* [Internet]. American Diabetes Association; 2014 [cited 2022 Aug 16];63:2229–31. Available from: <https://diabetesjournals.org/diabetes/article/63/7/2229/34347/Beyond-Erythropoiesis-Emerging-Metabolic-Roles-of>
16. Barbieri M, Ragno E, Benvenuti E, Zito GA, Corsi A, Ferrucci L, et al. New aspects of the insulin resistance syndrome: impact on haematological parameters.
17. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. 2018; Available from: <https://doi.org/10.7554/eLife.34408.001>
18. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. *Metab Syndr Relat Disord* [Internet]. *Metab Syndr Relat Disord*; 2008 [cited 2022 Oct 23];6:299–304. Available from: <https://pubmed.ncbi.nlm.nih.gov/19067533/>
19. Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan J, et al. The trans-ancestral genomic architecture of glycemic traits. *Nat Genet* [Internet]. *Nat Genet*; 2021 [cited 2022 Aug 27];53:840–60. Available from: <https://pubmed.ncbi.nlm.nih.gov/34059833/>
20. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell* [Internet]. *Cell*; 2020 [cited 2022 Aug 27];182:1214–1231.e11. Available from: <https://pubmed.ncbi.nlm.nih.gov/32888494/>
21. Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. *Cell* [Internet]. *Cell*; 2020 [cited 2022 Aug 27];182:1198–1213.e14. Available from: <https://pubmed.ncbi.nlm.nih.gov/32888493/>
22. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* [Internet]. *Nat Genet*; 2021 [cited 2022 Aug 27];53:1097–103. Available from: <https://pubmed.ncbi.nlm.nih.gov/34017140/>
23. Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.

- Nat Commun [Internet]. Nat Commun; 2018 [cited 2022 Jul 14];9. Available from: <https://pubmed.ncbi.nlm.nih.gov/30054458/>
24. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet [Internet]. Nat Genet; 2012 [cited 2022 Jul 14];44:991–1005. Available from: <https://pubmed.ncbi.nlm.nih.gov/22885924/>
 25. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet [Internet]. Hum Mol Genet; 2019 [cited 2022 Jul 14];28:166–74. Available from: <https://pubmed.ncbi.nlm.nih.gov/30239722/>
 26. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, Vanderweele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ [Internet]. British Medical Journal Publishing Group; 2021 [cited 2022 Jul 16];375. Available from: <https://www.bmj.com/content/375/bmj.n2233>
 27. Bowden J, Smith GD, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol [Internet]. Int J Epidemiol; 2015 [cited 2022 Jul 15];44:512–25. Available from: <https://pubmed.ncbi.nlm.nih.gov/26050253/>
 28. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol [Internet]. Genet Epidemiol; 2016 [cited 2022 Jul 15];40:304–14. Available from: <https://pubmed.ncbi.nlm.nih.gov/27061298/>
 29. Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol [Internet]. Int J Epidemiol; 2017 [cited 2022 Jul 15];46:1985–98. Available from: <https://pubmed.ncbi.nlm.nih.gov/29040600/>
 30. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat Med [Internet]. Stat Med; 2021 [cited 2022 Jul 1];40:5434–52. Available from: <https://pubmed.ncbi.nlm.nih.gov/34338327/>
 31. Sadreev II, Elsworth BL, Mitchell RE, Paternoster L, Sanderson E, Davies NM, et al. Navigating sample overlap, winner’s curse and weak instrument bias in Mendelian randomization studies using the UK Biobank. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; 2021 [cited 2022 Jul 14];2021.06.28.21259622. Available from: <https://www.medrxiv.org/content/10.1101/2021.06.28.21259622v1>
 32. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol [Internet]. Oxford Academic; 2019 [cited 2022 Jul 1];48:713–27. Available from: <https://academic.oup.com/ije/article/48/3/713/5238110>
 33. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care [Internet]. Diabetes Care; 2018 [cited 2022 Oct 23];41:356–63. Available from: <https://pubmed.ncbi.nlm.nih.gov/29203583/>

34. Ratajczak J, Zhang Q, Pertusini E, Wojczyk BS, Wasik MA, Ratajczak MZ. The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions--comparison to other cytokines and growth factors. *Leukemia* [Internet]. *Leukemia*; 1998 [cited 2022 Oct 23];12:371–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/9529132/>
35. Efron B, Tibshirani R. Improvements on Cross-Validation: The .632+ Bootstrap Method. *J Am Stat Assoc*. JSTOR; 1997;92:548.
36. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. *J Clin Invest* [Internet]. *J Clin Invest*; 2009 [cited 2022 Aug 30];119:315–22. Available from: <https://pubmed.ncbi.nlm.nih.gov/19164855/>
37. Ratajczak J, Zhang Q, Pertusini E, Wojczyk BS, Wasik MA, Ratajczak MZ. The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions--comparison to other cytokines and growth factors. *Leukemia* [Internet]. *Leukemia*; 1998 [cited 2022 Aug 30];12:371–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/9529132/>
38. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. *Lancet* [Internet]. *Lancet*; 2011 [cited 2022 Aug 27];378:156–67. Available from: <https://pubmed.ncbi.nlm.nih.gov/21705063/>
39. Sarnowski C, Leong A, Raffield LM, Wu P, de Vries PS, DiCorpo D, et al. Impact of Rare and Common Genetic Variants on Diabetes Diagnosis by Hemoglobin A1c in Multi-Ancestry Cohorts: The Trans-Omics for Precision Medicine Program. *Am J Hum Genet* [Internet]. *Am J Hum Genet*; 2019 [cited 2022 Aug 30];105:706–18. Available from: <https://pubmed.ncbi.nlm.nih.gov/31564435/>
40. Chai JF, Kao SL, Wang C, Jun-Yu Lim V, Khor IW, Dou J, et al. Genome-Wide Association for HbA1c in Malay Identified Deletion on SLC4A1 that Influences HbA1c Independent of Glycemia. *J Clin Endocrinol Metab* [Internet]. *J Clin Endocrinol Metab*; 2020 [cited 2022 Aug 30];105:3854–64. Available from: <https://pubmed.ncbi.nlm.nih.gov/32936915/>
41. Wu W-C, Lacy ME, Correa A, Carnethon M, Reiner AP, Eaton CB, et al. Association Between Hemoglobin A1c and Glycemia in African Americans with and without Sickle Cell trait and Whites, Results from CARDIA and the Jackson Heart Study. *J Diabetes Treat* [Internet]. NIH Public Access; 2018 [cited 2022 Aug 30];3. Available from: </pmc/articles/PMC8939875/>
42. Paterson AD. HbA1c for type 2 diabetes diagnosis in Africans and African Americans: Personalized medicine NOW! *PLoS Med* [Internet]. Public Library of Science; 2017 [cited 2022 Aug 30];14:e1002384. Available from: <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002384>
43. Lacy ME, Wellenius GA, Sumner AE, Correa A, Carnethon MR, Liem RI, et al. Association of Sickle Cell Trait With Hemoglobin A1c in African Americans. *JAMA* [Internet]. American Medical Association; 2017 [cited 2022 Aug 30];317:507–15. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2600468>
44. Lagou V, Mägi R, Hottenga JJ, Grallert H, Perry JRB, Bouatia-Naji N, et al. Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. *Nature*

Communications 2021 12:1 [Internet]. Nature Publishing Group; 2021 [cited 2022 Aug 29];12:1–18. Available from: <https://www.nature.com/articles/s41467-020-19366-9>

Figure Legends

Figure 1. Univariable Mendelian Randomization (MR) Analysis — Exposure: fasting insulin (FI), Outcome: haemoglobin (Hb)— (A) Scatter plot showing the single nucleotide polymorphisms (SNPs) associated with FI against SNPs associated with Hb (vertical and horizontal black lines around points show 95% confidence intervals (CI) for five different Mendelian Randomization (MR) association tests (B) Funnel plot of the effect size against the inverse of the standard error for each SNP

Figure 2. Univariable Mendelian Randomization (MR) Analysis — Exposure: fasting insulin (FI), Outcome: red cell count (RCC) and reticulocyte count (RETIC)— (A) Scatter plot showing the single nucleotide polymorphisms (SNPs) associated with FI against SNPs associated with RCC (vertical and horizontal black lines around points show 95% confidence intervals (CI) for five different Mendelian Randomization (MR) association tests (B) Funnel plot of the effect size against the inverse of the standard error for each SNP for FI against RCC (C) Scatter plot showing the single nucleotide polymorphisms (SNPs) associated with FI against SNPs associated with RETIC (vertical and horizontal black lines around points show 95% confidence intervals (CI) for five different Mendelian Randomization (MR) association tests (D) Funnel plot of the effect size against the inverse of the standard error for each SNP for FI against RETIC (

Figure 3. Univariable Mendelian Randomization (MR) Analysis — Exposure: fasting insulin (FI), Outcome: HbA1c— (B) Scatter plot showing the single nucleotide polymorphisms (SNPs) associated with FI against SNPs associated with HbA1c (vertical and horizontal black lines around points show 95% confidence intervals (CI) for five different Mendelian Randomization (MR) association tests (C) Funnel plot of the effect size against the inverse of the standard error for each SNP

Figure 4. Data from UHN cohort. Hexbin plots represent number of study participants with the observed and calculated values, where the colour and size of each individual hexagon correlates to the number of participants with the corresponding values. The red line represents the regression line for each cohort. (A) Association between Triglyceride Glucose Index and Hemoglobin (B) Association between Triglyceride Glucose Index and Glycation Gap in all participants (C) Association between Triglyceride Glucose Index and Glycation Gap in with pre-T2D (D) Association between Triglyceride Glucose Index and Glycation Gap in those with normoglycemia.

Table 2: Univariable MR analyses of fasting insulin (FI) and glycated hemoglobin (HbA1c) as outcome followed by multivariable MR adjusted for elevated fasting glucose (FG), type 2 diabetes (T2D) and increased haemoglobin (Hb)

Method	B	Standard Error	P	Egger-Intercept	p_{Egger}	Cochrane's Q	Q df	p_{α}	I^2	F
Univariable MR Analysis — Exposure: FI (49 SNPs, single nucleotide polymorphisms), Outcome: HbA1c										
MR Egger	0.226	0.436	0.608	2.70×10^{-5}	0.997	2610.360	47	0	98.199	19.221
Weighted median	0.348	0.055	1.72×10^{-10}							19.221
Inverse variance weighted	0.227	0.162	0.162			2610.361	48	0	98.161	19.221
Simple mode	0.689	0.097	5.57×10^{-9}							19.221
Weighted mode	0.432	0.118	6.42×10^{-4}							19.221
Multivariable MR Analysis — Exposure: FI adjusted FG (30 SNPs), Outcome: HbA1c										
Inverse Variance Weighted	-0.221	0.133	0.096			1111.614	82	3.42×10^{-180}	92.623	20.75
Multivariable MR Analysis — Exposure: FI adjusted T2D (21 SNPs), Outcome: HbA1c										
Inverse Variance Weighted	-0.305	0.126	0.016			1211.384	112	8.18×10^{-184}	90.754	14.524
Multivariable MR Analysis — Exposure: FI adjusted Hb (16 SNPs), Outcome: HbA1c										
Inverse Variance Weighted	0.363	0.110	9.14×10^{-4}			8336.312	403	0	95.166	4.547

Figure 2

MR Test

- Inverse variance weighted
- MR Egger
- Simple mode
- Weighted median
- Weighted mode





Figure 2

MR Method

Inverse variance weighted

MR Egger




2B

Figure 2

MR Test

- Inverse variance weighted
- MR Egger
- Simple mode
- Weighted median
- Weighted mode



2C

Figure 2

MR Method

Inverse variance weighted

MR Egger





Figure 3

MR Test

- Inverse variance weighted
- MR Egger
- Simple mode
- Weighted median
- Weighted mode



3A

Figure 3

MR Method

Inverse variance weighted

MR Egger






Figure 4



4A

Figure 4



Hundreds



1 3 5 7 9

Tens



1 3 5 7 9


Ones



1 3 5 7 9

4B

Figure 4



4C

Figure 4




Table of Contents — Supplemental Files

Supplementary File 1 – Cohorts for MR Analyses — Pg 2

Supplementary File 2 – STROBE Mendelian Randomization (MR) Checklist — Pg 3

Supplementary File 3 — Fasting Insulin instrument — Pg 11

Supplementary File 4– Reverse MR analyses. Exposure: Hb, RCC and RETIC. Outcome: Fasting insulin — Pg 14

Supplementary File 5 – Bidirectional MR analyses assessing the effect of Hb on HbA1c — Pg 15

Supplementary File 6 — Baseline characteristics for participants of observational study and descriptive statistics — Pg 22

Supplementary File 7 – Individual SNP Data and Leave-One-Out-Data Analyses exported from all univariable MR analyses conducted including primary analyses, secondary analyses and exploratory analyse —Pg 23

Supplementary File 1 – Cohorts

Summary statistics from the largest published genome wide association study (GWAS) in people of European ancestry were used in MR analyses (Supplementary Table 1) (18–24). Informed consent and institutional approval were previously obtained by the individual cohort investigators.

Table: Cohort details (all participants were of European descent)

Trait	Population cohort	Mean Age	% female	Sample size	Cases	Controls	PMID
Fasting Insulin (FI)	MAGIC	50.7	51.2	151,013	N/A	N/A	34059833
Waist-to-hip ratio (WHR)	GIANT/UK Biobank	55.5/56.9*	54.0/54.2*	694,649	N/A	N/A	30239722
Type 2 Diabetes (T2D)	DIAGRAM/GERA/UK Biobank	54.1/63.3/56.9*	50.1/59.0/54.2*	655,666	61,714	593,952	30054458
Fasting Glucose (FG)	MAGIC	50.9	47.7	133,010	N/A	N/A	22885924
Haemoglobin (Hb)	UK Biobank	56.7	54.9	563,946	N/A	N/A	32888493
Red Cell Count (RCC)	UK Biobank	56.7	54.9	545,203	N/A	N/A	32888493
Reticulocytes (RETIC) ***	UK Biobank	56.7	54.9	408,112	N/A	N/A	32888494
HbA1c**	MAGIC	52.3	57.9	146,806	N/A	N/A	34059833
HbA1c**/**	UK Biobank	56.7	54.9	389,889	N/A	N/A	34017140

*Study-specific characteristics were not available for all UK Biobank data and was extrapolated from data available.

^aOutput from MRC IEU GWAS pipeline analysis using Pheasant derived variables from UK Biobank, version 2: <https://doi.org/10.5523/bris.pnoat8cxo0u52p6ynfaekeigi>

** To minimize overlap, bidirectional MR analyses with FI was undertaken with HbA1c measure in the UK Biobank, but for WHR adjusted for BMI analyses HbA1c was assessed in MAGIC.

*** Estimated from available UK Biobank data (PMID 32888493) as data not available

Supplementary File 2. STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies^{1 2}

Item No.	Section	Checklist item	Page No.	Relevant text from manuscript
1	TITLE and ABSTRACT	Indicate Mendelian randomization (MR) as the study's design in the title and/or the abstract if that is a main purpose of the study	1	A Mendelian randomization study investigating the potential causal association between fasting insulin and erythrocytosis and its non-glycemic impact on HbA1c
INTRODUCTION				
2	Background	Explain the scientific background and rationale for the reported study. What is the exposure? Is a potential causal relationship between exposure and outcome plausible? Justify why MR is a helpful method to address the study question	4	Increasingly, haemoglobin A1c (HbA1c) has replaced fasting glucose and/or the 75 g oral glucose tolerance test to diagnose preT2D, T2D and T2D remission. HbA1c is also used to set glycemic targets for people with diabetes (7–9). Advantages to using HbA1c compared to fasting glucose, include convenience and use of an assay that is standardized, stable, reproducible with limited intraindividual variability (1,10). It provides an average measure of glycemia in the preceding 2 to 3 months (1). However, altered red cell lifespan and erythrocytosis, which is not routinely assessed, can affect HbA1c measurement by non-glycemic pathways, which has implications in patients with red cell disorders and haemoglobinopathies (1,11). In people without T2D, including those with preT2D, non-glycemic parameters are a major predictor of HbA1c: higher haemoglobin associates with lower HbA1c (12,13). Observational studies have also shown an association between IR/HI and increased haemoglobin and red cell count (14–16), but whether this association is causal is not established, nor is it known whether this impacts HbA1c measurement by non-glycemic pathways.
3	Objectives	State specific objectives clearly, including pre-specified causal hypotheses (if any). State that MR is a method that, under specific assumptions, intends to estimate causal effects	5	We undertook bidirectional MR to investigate potential causal associations between fasting insulin (FI) and erythrocytosis (haemoglobin, red cell count and reticulocyte count: primary outcome) in people of European ancestry using summary statistics from the largest genome wide association studies (GWAS). For our secondary outcome, we undertook multivariable MR to assess the non-glycemic effects of FI on HbA1c after adjusting for

elevated fasting glucose (FG) and type 2 diabetes (T2D).

METHODS			
4	Study design and data sources	Present key elements of the study design early in the article. Consider including a table listing sources of data for all phases of the study. For each data source contributing to the analysis, describe the following:	Summary statistics from the largest published genome wide association study (GWAS) in people of European ancestry were used in MR analyses
	a)	Setting: Describe the study design and the underlying population, if possible. Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection, when available.	5-6 Summary statistics from the largest published genome wide association study (GWAS) in people of European ancestry were used in MR analyses Table 1 – cohort details
	b)	Participants: Give the eligibility criteria, and the sources and methods of selection of participants. Report the sample size, and whether any power or sample size calculations were carried out prior to the main analysis	18 Table 1 – cohort details
	c)	Describe measurement, quality control and selection of genetic variants	5-6 Table 1 contains specific populations used. Summary statistics were taken from published GWAS
	d)	For each exposure, outcome, and other relevant variables, describe methods of assessment and diagnostic criteria for diseases	6 See above for b) c) d)
	e)	Provide details of ethics committee approval and participant informed consent, if relevant	Informed consent and institutional approval were previously obtained by the individual cohort investigators.
5	Assumptions	Explicitly state the three core IV assumptions for the main analysis (relevance, independence and exclusion restriction) as well assumptions for any additional or sensitivity analysis	6 MR assumptions: MR is based on three assumptions. First, the instrument is robustly associated with the exposure, therefore we only used SNPs that were genome-wide significantly associated for all the instruments (17). Second that the instrument does not influence the outcome via another pathway other than the outcome i.e. no horizontal pleiotropy (17). Finally, the instrument is not influenced by any confounders (17).
6	Statistical methods: main analysis	Describe statistical methods and statistics used	

	a)	Describe how quantitative variables were handled in the analyses (i.e., scale, units, model)	7-9	Betas are provided for continuous variables.
	b)	Describe how genetic variants were handled in the analyses and, if applicable, how their weights were selected	6	Genetic variants were weighted based on effect size in prior meta-GWAS.
	c)	Describe the MR estimator (e.g. two-stage least squares, Wald ratio) and related statistics. Detail the included covariates and, in case of two-sample MR, whether the same covariate set was used for adjustment in the two samples	6	IVWMR was performed by undertaking meta-analysis of the individual Wald ratio for each SNP in the instrument. By permitting a non-zero intercept, MR-Egger relaxes the assumption of no horizontal pleiotropy and returns an unbiased causal estimate, in the case of horizontal pleiotropy, providing that the horizontal pleiotropic effects are not correlated with the SNP-exposure effects (InSIDE assumption) (17,27).
	d)	Explain how missing data were addressed	7	Linkage disequilibrium (LD) pruning was used to select a proxy ($r^2 > 0.8$) if a SNP was not directly matched from the 1000 Genomes project
	e)	If applicable, indicate how multiple testing was addressed	NA	NA
7	Assessment of assumptions	Describe any methods or prior knowledge used to assess the assumptions or justify their validity	4	In people without T2D, including those with preT2D, non-glycemic parameters are a major predictor of HbA1c: higher haemoglobin associates with lower HbA1c (12,13). Observational studies have also shown an association between IR/HI and increased haemoglobin and red cell count (14–16), but whether this association is causal is not established, nor is it known whether this impacts HbA1c measurement by non-glycemic pathways.
8	Sensitivity analyses and additional analyses	Describe any sensitivity analyses or additional analyses performed (e.g. comparison of effect estimates from different approaches, independent replication, bias analytic techniques, validation of instruments, simulations)	6-7	For univariable MR, we used inverse weighted MR (IVWMR) and additional sensitivity analyses including MR-Egger, weighted median, weighted mode and leave-one-out analyses. Cochrane's Q test was used to assess heterogeneity, while leave-one-out analyses were conducted to assess if any MR estimate was biased by a single SNP potentially with horizontal pleiotropic effect (17) and the F statistic was calculated to assess the strength of the instrument exposure (17,30,31).
9	Software and pre-registration			

a) Name statistical software and package(s), including version and settings used	7	Univariable MR was conducted using the “TwoSampleMR” package in R (R studio® v1.3.1073 and R® v4.0.3). Linkage disequilibrium (LD) pruning was used to select a proxy ($r^2 > 0.8$) if a SNP was not directly matched from the 1000 Genomes project (Version 0.5.6, Released 2021-03-35). The “ggplot2” and “metaphor” packages in R were used to create plots. We undertook inverse variance weighted multivariable MR (IVW Multivariable MR) to assess the effect of FI on HbA1c after adjustment for FG and T2D as well as Hb (32). Multivariable MR was conducted using both the “TwoSampleMR”, “Multivariable MR” and “RMultivariable MR” packages in R (R studio® v1.3.1073 and R® v4.0.3) where the latter two packages assessed heterogeneity via Cochrane’s Q test and strength of the instrument via F statistics (30,32). Plots were generated using “plotobject”.
b) State whether the study protocol and details were pre-registered (as well as when and where)		The study was not pre-registered.

RESULTS

10 Descriptive data

a) Report the numbers of individuals at each stage of included studies and reasons for exclusion. Consider use of a flow diagram	18	Table 1 – cohort details
b) Report summary statistics for phenotypic exposure(s), outcome(s), and other relevant variables (e.g. means, SDs, proportions)	18	Table 1 – cohort details
c) If the data sources include meta-analyses of previous studies, provide the assessments of heterogeneity across these studies	18	Table 1 – cohort details – PMID to original GWAS studies are provided
d) For two-sample MR: <ul style="list-style-type: none"> i. Provide justification of the similarity of the genetic variant-exposure associations between the exposure and outcome samples ii. Provide information on the number of individuals who overlap between the exposure and outcome studies 	18 and 7	Cohort details in Table 1: exposure and outcome samples have similar mean age and %female. For our primary and secondary outcomes, there is no reported overlap between the cohorts. For our analyses of WHR adjusted for BMI and erythrocytosis, 456,426 participants from the UK Biobank composed approximately 67% of the GIANT/UK Biobank GWAS for WHR adjusted for BMI.

11 Main results

	a)	Report the associations between genetic variant and exposure, and between genetic variant and outcome, preferably on an interpretable scale	8-9	Associations were reported as increases or decreases outcome.
	b)	Report MR estimates of the relationship between exposure and outcome, and the measures of uncertainty from the MR analysis, on an interpretable scale, such as odds ratio or relative risk per SD difference	8-9	Beta and standard error were provided with p-values for continuous variables.
	c)	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA	NA
	d)	Consider plots to visualize results (e.g. forest plot, scatterplot of associations between genetic variants and outcome versus between genetic variants and exposure)	8-9	Figures and Supplemental Files – There are figures of forest plots, scatterplots and other graphs displaying the results visually.
12	Assessment of assumptions			
	a)	Report the assessment of the validity of the assumptions	8-9	MR-Egger intercept with p-value was reported as measure of horizontal pleiotropy for all significant associations.
	b)	Report any additional statistics (e.g., assessments of heterogeneity across genetic variants, such as I^2 , Q statistic or E-value)	8-9	Assessment of heterogeneity across genetic variants were provided for all analyses including I2 and Q statistics.
13	Sensitivity analyses and additional analyses			
	a)	Report any sensitivity analyses to assess the robustness of the main results to violations of the assumptions	8-9	MR- Egger, weighted-median and weighted-mode analyses were completed.
	b)	Report results from other sensitivity analyses or additional analyses	8-9	Visualization of scatter plots, funnel plots and leave-one-out analyses were completed.
	c)	Report any assessment of direction of causal relationship (e.g., bidirectional MR)	8-9	Bidirectional MR was completed for all univariable MR analyses.
	d)	When relevant, report and compare with estimates from non-MR analyses	NA	NA
	e)	Consider additional plots to visualize results (e.g., leave-one-out analyses)	8-9	See figures and supplemental files.
DISCUSSION				
14	Key results	Summarize key results with reference to study objectives	10	Our MR analysis suggests that this association is causal and further suggests that increased FI after adjustment for FG and T2D may reduce HbA1c.

			MR also indicates a bidirectional inverse relationship between Hb and HbA1c. Collectively, these data suggest that increased IR/HI mediated erythrocytosis may potentially lower HbA1c by non-glycemic effects.	
15	Limitations	Discuss limitations of the study, taking into account the validity of the IV assumptions, other sources of potential bias, and imprecision. Discuss both direction and magnitude of any potential bias and any efforts to address them	11	Our findings may not apply to other ethnic groups given that we used populations with European ancestry only. This may especially be a concern in populations with higher prevalence of hemoglobinopathies and red cell disorders (38–42). Additionally, analyses were not stratified by sex, which is a major determinant of body composition and IR/HI (34). There may also be a relationship between sex hormones such as estradiol and sex hormone binding globulin and HbA1c (43). Finally, there was significant overlap between our exposure and outcome cohorts for our exploratory analyses of the association between waist-hip ratio, erythrocytosis and HbA1c.
16	Interpretation			
	a)	Meaning: Give a cautious overall interpretation of results in the context of their limitations and in comparison with other studies	10	Our MR analysis suggests that this association is causal and further suggests that increased FI after adjustment for FG and T2D may reduce HbA1c. MR also indicates a bidirectional inverse relationship between Hb and HbA1c. Collectively, these data suggest that increased IR/HI mediated erythrocytosis may potentially lower HbA1c by non-glycemic effects. In exploratory analyses we also report that increased WHR adjusted for BMI, a phenotype associated with IR/HI (26,33) may increase erythrocytosis but we were unable to confirm a significant non-glycemic impact on HbA1c warranting caution in interpreting the data.
	b)	Mechanism: Discuss underlying biological mechanisms that could drive a potential causal relationship between the investigated exposure and the outcome, and whether the gene-environment equivalence assumption is reasonable. Use causal language carefully, clarifying that IV estimates may provide causal effects only under certain assumptions	10	Increased FI is a recognised manifestation of IR. Some features of IR/HI such as increased hepatic glucose production are likely a consequence of reduced insulin action, while others such as hepatic steatosis and dyslipidemia are likely due to increased insulin action via signaling pathways that are not perturbed in IR (35). In vitro studies suggest that insulin can increase erythrocytosis (36), suggesting that increased insulin action may underlie the increased in erythrocytosis with IR/HI.

			Further studies are needed to confirm these findings and explore underlying mechanisms.
	c)	Clinical relevance: Discuss whether the results have clinical or public policy relevance, and to what extent they inform effect sizes of possible interventions	11 In conclusion, our data suggests that increased FI may increase erythrocytosis and potentially lower HbA1c by non-glycemic effects. These findings might have implications for the diagnoses of preT2D and T2D, its treatment and remission and merits further confirmatory studies.
17	Generalizability	Discuss the generalizability of the study results (a) to other populations, (b) across other exposure periods/timings, and (c) across other levels of exposure	11 In conclusion, our data suggests that increased FI may increase erythrocytosis and potentially lower HbA1c by non-glycemic effects. These findings might have implications for the diagnoses of preT2D and T2D, its treatment and remission and merits further confirmatory studies. Our findings may not apply to other ethnic groups given that we used populations with European ancestry only. This may especially be a concern in populations with higher prevalence of hemoglobinopathies and red cell disorders (38–42). Additionally, analyses were not stratified by sex, which is a major determinant of body composition and IR/HI (34). There may also be a relationship between sex hormones such as estradiol and sex hormone binding globulin and HbA1c (43). Finally, there was significant overlap between our exposure and outcome cohorts for our exploratory analyses of the association between waist-hip ratio, erythrocytosis and HbA1c.
OTHER INFORMATION			
18	Funding	Describe sources of funding and the role of funders in the present study and, if applicable, sources of funding for the databases and original study or studies on which the present study is based	11 SD is funded by CIHR, Heart & Stroke Foundation of Canada and Banting & Best Diabetes Centre (DH Gales Family Charitable Foundation New Investigator Award and a Reuben & Helene Dennis Scholar in Diabetes Research).
19	Data and data sharing	Provide the data used to perform all analyses or report where and how the data can be accessed, and reference these sources in the article. Provide the statistical code needed to reproduce the results in the article, or report whether the code is publicly accessible and if so, where	All data is public access. Please refer to Table 1 for cohort details. TwoSampleMR R code and MVMR code is also publicly available.

20	Conflicts of Interest	All authors should declare all potential conflicts of interest	12	None
----	------------------------------	--	----	------

This checklist is copyrighted by the Equator Network under the Creative Commons Attribution 3.0 Unported (CC BY 3.0) license.

1. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) Statement. JAMA. 2021;under review.
2. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR): Explanation and Elaboration. BMJ. 2021;375:n2233.

Supplementary File 3. Fasting Insulin instrument.

Chromosome	Phenotype	SNP	effect_allele	other_allele	eaf	beta	se	pval
1	FI	rs6674544	A	G	0.57	0.018	0.002	6.97E-21
2	FI	rs77935490	A	T	0.21	0.014	0.003	1.07E-08
2	FI	rs61007968	C	G	0.21	0.011	0.003	2.63E-06
2	FI	rs1260326	T	C	0.39	0.023	0.002	8.42E-38
2	FI	rs2252867	T	C	0.64	0.007	0.002	1.46E-05
2	FI	rs6713419	T	C	0.63	0.019	0.002	1.44E-24
2	FI	rs75265117	C	G	0.88	0.028	0.003	1.54E-24
2	FI	rs1128249	T	G	0.39	-0.02	0.002	7.71E-28
2	FI	rs13389219	T	C	0.39	-0.02	0.002	5.84E-28
2	FI	rs2943646	A	G	0.37	0.025	0.002	8.47E-39
2	FI	rs2972145	T	C	0.37	0.025	0.002	6.08E-38
2	FI	rs17508368	T	C	0.06	0.019	0.004	2.12E-06
3	FI	rs308971	A	G	0.87	0.022	0.003	3.91E-13
3	FI	rs11712037	C	G	0.87	0.028	0.003	2.10E-21
3	FI	rs35000407	T	G	0.86	0.026	0.003	1.50E-21
3	FI	rs9819511	T	C	0.3	0.014	0.002	2.26E-08
3	FI	rs17331151	T	C	0.11	0.016	0.003	1.52E-08
3	FI	rs11708067	A	G	0.78	0.014	0.002	1.30E-09
3	FI	rs62271373	A	T	0.06	0.026	0.005	1.60E-08
4	FI	rs2276936	A	C	0.5	0.012	0.002	4.25E-11
4	FI	rs3775380	A	G	0.5	0.012	0.002	1.48E-11
4	FI	rs9884482	T	C	0.61	0.013	0.002	2.88E-11
4	FI	rs10010325	A	C	0.48	0.012	0.002	4.05E-11
4	FI	rs7654571	A	G	0.24	0.012	0.002	7.77E-08
4	FI	rs11727676	T	C	0.91	-0.02	0.004	2.90E-08
4	FI	rs6855363	T	C	0.68	0.013	0.002	4.04E-08
5	FI	rs4865796	A	G	0.68	0.017	0.002	7.33E-17
5	FI	rs459193	A	G	0.27	0.018	0.002	1.12E-18
5	FI	rs3936511	A	G	0.82	0.019	0.003	2.81E-14
5	FI	rs1023667	A	G	0.27	-0.01	0.002	5.70E-07
6	FI	rs116684538	A	T	0.22	0.014	0.003	1.31E-07
6	FI	rs116141873	T	G	0.04	0.043	0.006	1.42E-11
6	FI	rs2780215	A	G	0.96	0.039	0.006	1.06E-09

Supplementary File 3. Fasting Insulin instrument.

6	FI	rs1187129	A	G	0.03	-	0.007	1.41E-05
6	FI	rs5875762	C	CA	0.31	-	0.003	1.53E-03
6	FI	rs998584	A	C	0.49	0.012	0.002	2.31E-10
6	FI	rs9472135	T	C	0.7	0.011	0.002	4.21E-08
6	FI	rs1474696	A	G	0.49	-	0.002	3.02E-16
6	FI	rs2745353	T	C	0.52	0.015	0.002	4.63E-16
6	FI	rs632057	T	G	0.4	0.008	0.002	1.37E-05
6	FI	rs73013411	A	C	0.13	-	0.003	2.08E-08
6	FI	rs4709746	T	C	0.13	-	0.003	2.97E-08
7	FI	rs2282930	A	G	0.23	-	0.003	1.67E-05
7	FI	rs2108349	A	G	0.66	-	0.002	1.13E-08
7	FI	rs848494	A	G	0.74	0.009	0.002	9.25E-06
7	FI	rs13234269	A	T	0.48	-	0.002	1.27E-08
7	FI	rs972283	A	G	0.47	-	0.002	1.09E-08
8	FI	rs330945	T	C	0.63	0.014	0.002	1.82E-11
8	FI	rs7012637	A	G	0.48	-	0.002	1.48E-29
8	FI	rs7012814	A	G	0.48	-	0.002	8.34E-30
8	FI	rs4841132	A	G	0.11	0.026	0.003	3.83E-20
8	FI	rs12541800	A	G	0.49	0.011	0.002	6.17E-07
8	FI	rs12056334	A	C	0.13	0.005	0.003	1.16E-01
8	FI	rs13258890	T	C	0.77	0.013	0.003	2.77E-08
9	FI	rs4339696	T	G	0.48	0.009	0.002	1.52E-07
9	FI	rs11138325	T	C	0.58	-	0.002	5.39E-08
9	FI	rs75179845	T	C	0.91	-	0.004	6.05E-11
9	FI	rs8176693	T	C	0.1	0.02	0.003	1.10E-10
10	FI	rs10761762	T	C	0.51	0.008	0.002	1.98E-05
10	FI	rs118164457	T	C	0.96	-	0.006	3.86E-10
10	FI	rs12769346	T	G	0.86	-	0.003	1.20E-08
10	FI	rs11191559	T	C	0.09	-	0.003	1.27E-05
10	FI	rs7903146	T	C	0.27	-	0.002	1.24E-09
10	FI	rs7071062	T	C	0.97	0.019	0.007	1.19E-02
11	FI	rs2845885	T	C	0.93	-0.02	0.004	1.18E-08

Supplementary File 3. Fasting Insulin instrument.

11	FI	rs3781926	T	C	0.36	0.009	0.002	3.26E-05
12	FI	rs12369443	A	G	0.78	0.01	0.002	6.66E-06
12	FI	rs2054435	A	G	0.22	0.015	0.003	9.50E-09
12	FI	rs6487237	A	C	0.78	0.015	0.003	4.68E-09
12	FI	rs10842708	A	G	0.74	-0.01	0.002	1.08E-05
12	FI	rs111264094	C	G	0.97	0.057	0.009	1.64E-09
12	FI	rs1351394	T	C	0.49	0.011	0.002	2.71E-09
12	FI	rs7968682	T	G	0.51	0.011	0.002	3.17E-09
12	FI	rs73343765	A	G	0.006	-0.19	0.053	2.14E-04
12	FI	rs1402013	A	G	0.35	0.009	0.002	1.31E-06
12	FI	rs860598	A	G	0.82	0.018	0.003	6.88E-12
12	FI	rs35747	A	G	0.82	0.017	0.003	2.68E-11
12	FI	rs7133378	A	G	0.32	0.013	0.002	6.00E-11
12	FI	rs7975482	A	G	0.67	0.012	0.002	1.97E-10
13	FI	rs9521730	A	G	0.34	0.009	0.002	1.15E-06
16	FI	rs2024449	T	C	0.57	0.01	0.002	4.81E-07
18	FI	rs12454712	T	C	0.58	0.014	0.003	1.78E-09
19	FI	rs1799815	A	G	0.06	0.033	0.006	9.24E-08
19	FI	rs4804833	A	G	0.39	0.01	0.002	6.59E-06
19	FI	rs10422861	T	C	0.67	0.013	0.002	6.65E-11
19	FI	rs731839	A	G	0.66	0.012	0.002	3.87E-11
19	FI	rs339525	T	G	0.26	0.007	0.003	2.07E-04
19	FI	rs200172871	C	CT	0.48	0.011	0.003	1.71E-05
20	FI	rs979012	T	C	0.34	0.011	0.002	4.81E-07
20	FI	rs285171	C	G	0.16	0.012	0.003	8.94E-06
20	FI	rs1999536	C	G	0.55	0.012	0.002	1.32E-09
20	FI	rs1206760	A	G	0.54	0.011	0.002	8.82E-10
21	FI	rs200678953	T	TATATGTTATATAC	0.37	0.014	0.003	2.04E-08
X	FI	rs2497942	C	G	0.81	0.011	0.003	1.61E-06
X	FI	rs12007422	T	G	0.62	0.011	0.002	1.10E-06

Supplementary File 5 — Bidirectional MR analyses assessing the effect of Hb on HbA1c

Description of Different Figure Types


- A) Scatter plot showing the single nucleotide polymorphisms (SNPs) associated with Hb against SNPs associated with HbA1c as the outcome (vertical and horizontal black lines around points show 95% confidence intervals (CI)) for five different Mendelian Randomization (MR) association tests.
- B) Funnel plot of the effect size against the inverse of the standard error for each SNP.

Exposure: Hb, Outcome: HbA1c


Figures of Scatter Plot of MR Methods (A) and Funnel Plot (B)

MR Test

- Inverse variance weighted
- MR Egger
- Simple mode
- Weighted median
- Weighted mode



A





Exposure: HbA1c, Outcome: Hb

Figures of Scatter Plot of MR Methods (A) and Funnel Plot (B)

MR Test

- Inverse variance weighted
- MR Egger
- Simple mode
- Weighted median
- Weighted mode





Supplemental File 6: Baseline characteristics for participants of observational study and descriptive statistics.

Table: Baseline characteristics for participants of observational study

Characteristic	Healthy Participants, N = 6,504 ¹	Participants with Pre-T2D, N = 1,096 ¹	p-value ²
Sex			0.076
Female	3,147 (48%)	562 (51%)	
Male	3,357 (52%)	534 (49%)	
Age (years)	50 (41, 58)	56 (49, 61)	<0.001
HbA1c (%)	5.40 (5.20, 5.60)	6.10 (6.00, 6.20)	<0.001
Fasting Glucose (mmol/L)	5.10 (4.70, 5.50)	5.70 (5.20, 6.20)	<0.001
Triglyceride (mmol/L)	1.16 (0.85, 1.68)	1.33 (0.99, 1.92)	<0.001
HDL Cholesterol (mmol/L)	1.29 (1.07, 1.57)	1.19 (1.01, 1.43)	<0.001
Hemoglobin (g/L)	145 (136, 154)	144 (134, 153)	<0.001
Triglyceride Glucose Index	8.46 (8.12, 8.85)	8.71 (8.36, 9.08)	<0.001
Predicted A1c, adjusted for age, sex (%)	5.04 (4.97, 5.11)	5.14 (5.06, 5.23)	<0.001
Glycation Gap ³	0.36 (0.12, 0.57)	1.01 (0.89, 1.13)	<0.001
¹ Median (IQR); n (%)			
² Wilcoxon rank sum test; Pearson's Chi-squared test			
³ Actual HbA1c – Predicted HbA1c			

Table: Linear Regression for Triglyceride Glucose Index (exposure) on Glycation Gap (outcome)*

Population (n)	Beta	Standard error	y-intercept	p-value
Pre-T2D (1096)	-0.087	0.009	1.77	<0.0001
Healthy (6504)	0.023	0.007	0.14	<0.0001
HbA1c < 5% (681)	0.071	0.01	0.41	<0.0001
HbA1c 5 – 5.4% (2948)	0.047	0.005	0.6	<0.0001
HbA1c 5.5 – 5.9% (2875)	0.054	0.006	1.06	<0.0001

*calculated as Actual HbA1c – Predicted HbA1c using model adjusted for age, sex (18)

Supplementary File 7

Link: https://www.dropbox.com/s/827zwgfwszefe36/SF8_FP_LOO_Export_All_Analyses.xlsx?dl=0